Bio-Rad Laboratories (BIO) vs Bruker (BRKR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bruker (BRKR) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 72.8% versus a gain of 24.1%. Over five years, BRKR leads with a -22.7% price change compared with -49.0% for BIO. Bio-Rad Laboratories is the larger company by market cap ($9.84 billion vs $9.10 billion), about 1.1 times the size, while Bruker is growing revenue faster (+2.1% vs +0.7%).
On valuation, Bruker trades at a lower forward P/E (24.8x vs 37.1x for Bio-Rad Laboratories). Bruker pays a dividend yielding 0.33%, while Bio-Rad Laboratories does not currently pay one. Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -0.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | BRKR |
|---|---|---|
| Share price | $367.92 | $59.72 |
| Market cap | $9.84B | $9.10B |
| 1-day change | -0.25% | -1.29% |
| YTD return | +21.43% | +26.77% |
| 1-year return | +24.08% | +72.80% |
| 5-year return | -49.00% | -22.67% |
| P/E ratio (TTM) | 46.63 | — |
| Forward P/E | 37.10 | 24.76 |
| EPS (TTM) | $7.89 | $-0.70 |
| Dividend yield | 0.00% | 0.33% |
| Annual dividend | $0.00 | $0.20 |
| Revenue (latest FY) | $2.58B | $3.44B |
| Revenue growth (YoY) | +0.65% | +2.08% |
| Net income (latest FY) | $759.90M | $-8.60M |
| Gross margin | 51.87% | 45.91% |
| Operating margin | 1.83% | 1.98% |
| Net margin | 29.42% | -0.25% |
| 52-week high | $396.23 | $66.98 |
| 52-week low | $236.73 | $32.37 |
| Distance from 52-week high | -7.14% | -10.84% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -10.76% | +5.91% |
| Average volume | 277.32K | 2.22M |
| Shares outstanding | 21.68M | 152.36M |
| Employees | 7,450 | 11,085 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BRKR has outperformed BIO by 48.7 percentage points over the past year.
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -0.3 cents for Bruker.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About Bruker
BRKR stock →Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees
BIO vs BRKR FAQ
Which is bigger, Bio-Rad Laboratories or Bruker?
Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.84B compared with $9.10B for Bruker (BRKR).
Which stock has performed better over the past year, BIO or BRKR?
BRKR returned +72.80% over the past 12 months, compared with +24.08% for BIO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bio-Rad Laboratories or Bruker?
Bruker pays a dividend yielding 0.33%, while Bio-Rad Laboratories does not currently pay a regular dividend.
Are Bio-Rad Laboratories and Bruker in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.